The data represent the concentrations of specific neutralizing antibodies following infant immunization against yellow fever. We used a microneutralization assay to measure protective antibodies against yellow fever virus in 587 Malian and 436 Ghanaian children vaccinated around age 9 months, and followed for 4.5 years (Mali), or 2.5 and 6 years (Ghana). We standardized antibody concentrations with reference to the yellow fever WHO International Standard. The serum samples used in this study, and the sample metadata included in the present dataset originate from trials of the meningococcal group A conjugate vaccine, MenAfriVac, namely the PsATT-004 (phase II) and Pers-004 (phase IV) studies in Ghana, and the PsATT-007 (phase III) and Pers-007 (phase IV) studies in Mali (clinical trial registry numbers ISRCTN82484612, ISRCTN10763234, PACTR201110000328305, and ISRCTN37623829). MenAfriVac was developed by PATH and Serum Institute India Pvt. Ltd. (SIIPL). This dataset consists of three files: 1. Ghana group data | Tab-delimited text file: Yellow_fever_nAb_Ghana.txt 2. Mali group data | Tab-delimited text file: Yellow_fever_nAb_Mali.txt 3. Data dictionary | PDF file: Yellow_fever_nAb_data_dictionary.pdf Access is currently on a restricted basis but open access will be provided from the time of publication of the research article.

{"references": ["Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO, Mej\u00eda JE. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. The Lancet Infectious Diseases (2019) https://doi.org/10.1016/S1473-3099(19)30323-8"]}